| Target |
Useful Application/Cells/ Tumors Identified |
| A |
|
| ACTH |
Subset of pituitary tumors |
| Actin, muscle specific (HHF-35) |
Smooth, skeletal muscle differentiation: leiomyosarcoma, rhabdomyosarcoma, myofibroblasts, myoepithelium |
| Actin, smooth muscle alpha |
(1A4) Smooth muscle differentiation: leiomyosarcoma, myofibroblasts, myoepithelium |
| Adenovirus |
Adenovirus identification |
| ALK protein (p80) |
Anaplastic large cell lymphoma (subset with t(2;5)) |
| Alpha-1-antitrypsin |
Alpha-1-antitrypsin deficiency |
| Alpha-fetoprotein |
Yolk sac tumors, hepatocellular carcinoma |
| AMACR (p504s) |
Prostate carcinoma marker |
| Amyloid type analysis |
Amyloid P, Amyloid A, Transthyretin, Kappa, Lambda, Β-Amyloid, Congo Red, Β-2-Microglobulin |
| Amyloid A |
Subtype of amyloid |
| Amyloid beta |
Subtype of amyloid, Alzheimer disease |
| Amyloid P component |
Amyloid (all subtypes) |
| Androgen receptor |
Prognostic and predictive marker in prostate cancer |
| B |
|
| bcl-2 |
Nodular lymphoma v. reactive hyperplasia, subset of lymphomas, carcinomas, and sarcomas |
| bcl-6 |
Follicular lymphoma |
| Ber-Ep4 |
(Epithelial glycoprotein) Subset of adenocarcinoma, negative on mesothelioma |
| Beta-2-microglobulin |
Amyloid subtype |
| Beta-catenin |
Nuclear localization in colorectal adenocarcinoma and abdominal fibromatosis |
| Bg8 |
Blood group antigen (Lewis Y); subset of adenocarcinoma, negative on mesothelioma |
| βHCG |
See Chorionic gonadotropin |
| BK virus |
See SV40 |
| Blood group A |
Identification of tissue 'floaters' |
| Blood group B |
Identification of tissue 'floaters' |
| Bob-1 |
B cell transcription factor |
| C |
|
| C3 (complement) |
For skin immunofluorescence studies* |
| c-kit (CD117) |
Gastrointestinal stromal tumors, mast cells |
| CA-125 |
Not offered; see WT-1 |
| Calcitonin |
Thyroid C cells, medullary carcinoma |
| Caldesmon |
Endometrial stromal tumors vs. smooth muscle tumors |
| Calponin |
Myoepithelial marker, in situ v. infiltrating breast carcinoma |
| Calretinin |
Mesothelioma |
| Caspase 3 fragment |
Apoptotic cells |
| CD1a |
Langerhans cells, histiocytosis X |
| CD2 |
T cell subset |
| CD3 |
Mature T cells, T cell lymphoma |
| CD4 |
T cell subset |
| CD5 |
T cells, mantle zone cells, small lymphocytic B cell lymphoma |
| CD7 |
T cell marker |
| CD8 |
T cell subset |
| CD10 (CALLA) |
Subset of lymphomas and carcinomas |
| CD15 |
Reed-Sternberg cells of Hodgkin lymphoma, neutrophils, some adenocarcinomas |
| CD20 |
B cell lymphomas, target of immunotherapy |
| CD21 |
B cell and follicular dendritic cells and tumors |
| CD22 |
B cell lymphomas, target of immunotherapy |
| CD23 |
Small lymphocytic (B cell) lymphoma |
| CD25 (IL-2Rβ) |
Lymphoid activation marker, target of immunotherapy |
| CD30 (K-1 antigen) |
Hodgkin disease, anaplastic large cell lymphoma, embryonal CA |
| CD31 |
Endothelial cells and tumors |
| CD33 |
Helps to establish myeloid lineage in poorly differentiated hematolymphoid neoplasms. CD33 is also a therapeutic target for the drug Myelotarg, used in treating myeloid neoplasms |
| CD34 |
Endothelium and endothelial tumors, leukemias, subset of mesenchymal tumors |
| CD35 |
Follicular dendritic cells and tumors |
| CD43 |
T cells, leukemias, macrophages, often coexpressed in B cell lymphomas |
| CD45 |
(Common leukocyte antigen, T200 antigen) Marker of lymphocytes, hematolymphoid processes |
| CD52 (CAMPATH 1H) (requires frozen tissue) |
T cells, B cells |
| CD56 (NCAM) |
Natural killer cells (NK/T cell lymphoma), neural tumors |
| CD57 |
Nerve sheath tumors, T cells in NLPHL |
| CD66 |
(CEA family) Adenocarcinoma subset, hepatocellular carcinoma (bile canalicular pattern), negative on mesothelioma |
| CD68 |
Macrophage marker |
| CD79a |
B cell lymphomas |
| CD99 |
PNET/Ewing tumors |
| CD117 (c-kit) |
Gastrointestinal stromal tumors, mast cells |
| CD138 |
Plasma cells and myeloma |
| CD163 |
Most specific IHC marker currently available to ID macrophages/histiocytes (but not Langerhans cells) |
| CDX2 |
Colorectal adenocarcinomas and subset of other GI adenocarcinomas |
| CEA (CD66e) |
Adenocarcinoma subset, negative on mesothelioma |
| CEA family (CD66) |
Adenocarcinoma subset, hepatocellular carcinoma (bile canalicular pattern), negative on mesothelioma |
| Chlamydia |
Chlamydia identification (all species) |
| Chorionic gonadotropin |
(HCG, ΒHCG) Trophoblasts and choriocarcinoma |
| Chromogranin A |
Neuroendocrine differentiation |
| Collagen, type IV |
Basement membrane protein, subset of mesenchymal tumors |
| Common leukocyte antigen |
See CD45 |
| Complement C3 |
See C3 |
| COX-2 (cyclo-oxygenase-2) |
Predictor of treatment response |
| CXCL13 |
Sensitive marker for angioimmunoblastic T cell lymphomas; expressed in developing/evolving processes as well as in more established cases |
| Cyclin D1 |
Mantle cell lymphoma |
| Cytokeratin 1/10 (34βB4) |
Squamous cell carcinoma |
| Cytokeratin 5 |
(CK 5/6) mesothelioma, squamous cell carcinoma, transitional cell carcinoma |
| Cytokeratin 7 |
Carcinoma subset |
| Cytokeratin 8 |
(Low MW cytokeratin) All non-squamous carcinomas |
| Cytokeratin 17 |
Carcinoma subset |
| Cytokeratin 19 |
Carcinoma subset |
| Cytokeratin 20 |
GI tumors, transitional cell carcinoma, Merkel cell tumors |
| Cytokeratin, high MW (34βE12) |
Carcinoma subset; normal or hyperplastic prostate v. prostatic carcinomas |
| Cytokeratins (pan) |
(OSCAR, AE1/AE3) All epithelial cells and all carcinomas |
| Cytomegalovirus |
CMV identification |
| D |
|
| D2-40 (Podoplanin) |
See Podoplanin |
| DBA.44 |
See Hairy cell leukemia |
| Desmin |
Skeletal, smooth muscle tumors |
| DOG1 |
Specifically expressed in GISTs (GastroIntestinal Stromal Tumors) |
| E |
|
| E-cadherin |
Positive on ductal, negative on lobular breast carcinomas |
| EBV (EBER1) |
(Via in situ hybridization) Post transplantation lymphoproliferative disorder, Hodgkin lymphoma, EBV identification |
| EBV - LMP |
LMP = Latent membrane protein of EBV |
| EGFR |
(Epidermal growth factor receptor) prognostic marker in certain carcinomas |
| EMA |
(Epithelial membrane antigen) Some carcinomas, meningioma, anaplastic large cell lymphoma |
| Epithelial glycoprotein (Ber-Ep4) |
Subset of adenocarcinomas, negative on mesothelioma |
| Estrogen receptor (ER) |
Prognostic and predictive marker in breast and other carcinomas |
| F |
|
| Factor VIII related antigen |
(von Willebrand factor) endothelial cells, megakaryocytes |
| Factor XIIIa |
Dermal dendrocytes, dermatofibroma |
| Fascin |
Hodgkin lymphoma |
| Filaggrin |
Squamous cell differentiation marker |
| FLI-1 |
Presence of EWS-FLI-1 fusion product secondary to (11;22) (q24;q12) translocation characteristic of PNET Ewing sarcoma |
| FOXP1 |
Useful as part of a panel of tests to distinguish GCB from non-GCB DLBCL |
| FSH |
Subset of pituitary tumors |
| G |
|
| Galectin-3 |
Useful in differentiating malignant v. benign thyroid tumors |
| Gastrin |
Subset of pancreatic islet cell tumors |
| GCDFP-15 (Brst2) |
Breast, salivary, sweat gland tumors |
| GCET |
Useful as part of a panel of tests to distinguish GCB from non-GCB DLBCL |
| GFAP (Glial-fibrillary acidic protein) |
Glioma |
| Glucagon |
Subset of pancreatic islet cell tumors |
| Glycophorin A |
Erythroid marker |
| Glypican-3 (GPC3) |
Distinguishes hepatocellular carcinoma from non-neoplastic liver |
| gp100 (HMB-45) |
Melanoma |
| gp200 renal tubular antigen |
Not currently available |
| Granzyme |
Not offered; see TIA-1 |
| Growth hormone |
Subset of pituitary tumors |
| H |
|
| Hairy cell leukemia |
(DBA.44) Hairy cell leukemia |
| HBME-1 |
Mesothelioma, thyroid carcinoma |
| HCG |
See Chorionic gonadotropin |
| Helicobacter pylori |
Positive identification of Helicobacter |
| Hemoglobin |
Erythroid marker |
| Hepatitis B core Ag |
Hepatitis B virus identification |
| Hepatitis B surface Ag |
Hepatitis B virus identification |
| HepPar1 Antigen |
Hepatocellular and hepatoid carcinomas |
| HER2 by FISH |
Poor prognostic factor, predictor of treatment response in breast carcinoma |
| HER2 by IHC |
Poor prognostic factor, predictor of treatment response in breast carcinoma |
| HER2 HercepTest™ |
Poor prognostic factor, predictor of treatment response in breast carcinoma |
| Herpes virus |
HSVI, HSVII identification |
| HHV8 (human Herpes virus 8) |
Kaposi sarcoma, HIV-related lymphomas |
| HLA-DR |
Useful in differentiating acute myeloid leukemias of non-promyelocytic type (non-Me AMLs) from acute promyelocytic leukemias (AML M3). Can also help distinguish monocytic proliferations (HLA-DR+) from granulocytic proliferations (generally HLA-DR-). |
| HMB-45 antigen |
(gp100) melanoma |
| hMLH1 |
See MLH1 |
| hMSH2 |
See MSH2 |
| hMSH6 |
See MSH6 |
| hPMS2 |
See PMS2 |
| HPV |
Not offered, see p16 |
| I |
|
| IgA |
Subset of myeloma: also for skin immunofluorescence studies* |
| IgD |
Subset of myeloma: also for skin immunofluorescence studies* |
| IgG |
Subset of myeloma: also for skin immunofluorescence studies* |
| IgG4 |
Expressed in IgG4-related sclerosing diseases (IgG4-related autoimmune disease). It is important to recognize IgG4-related sclerosing diseases because of (1) the potential to mistake them for lymphoma, and (2) they responds favorably to steroid treatment |
| IgM |
Subset of myeloma: also for skin immunofluorescence studies* |
| Inhibin-alpha |
Granulosa cell tumors, adrenal cortical tumors |
| INI-1 |
INI-1 & Lack of INI-1 protein expression has been described as a characteristic finding to distinguish rhabdoid tumors and other malignant central nervous system tumors |
| Insulin |
Subset of pancreatic islet cell tumors |
| J |
|
| JC virus (Jamestown Canyon) |
see SV40 |
| K |
|
| Kappa light chains |
Myeloma, some B cell lymphomas |
| Ki-1 antigen (CD30) |
Hodgkin lymphoma, anaplastic large cell lymphoma, embryonal carcinoma |
| Ki-67 antigen |
Cell proliferation marker (non-GO) |
| L |
|
| Lambda light chains |
Myeloma, some B cell lymphomas |
| Legionella |
Legionella identification |
| Leutinizing hormone |
Subset of pituitary tumors |
| Lysozyme |
Granulocytes & histocytes, marker of leukemias |
| M |
|
| Macrophage |
(HAM56) macrophage |
| Mammaglobin |
Breast cancer marker |
| MART-1 antigen |
(Melan A) Melanoma, adrenal cortical and ovarian stromal tumors |
| Maspin |
Myoepithelial marker. This antibody will be of use in a panel of other antibodies to determine the presence of invasive breast carcinoma. |
| Melanoma specific antigen |
(gp100 as identified by HMB-45) Melanoma |
| Mesothelin |
Ovarian (serous papillary) carcinoma, mesothelioma, pancreatic carcinomas |
| Mitochondria |
Oncocytomas |
| Microphthalmia transcription factor |
See MTF |
| MLH1 |
(Mismatch repair gene product) Subset of colorectal CA w/MSI |
| MOC-31 |
Adenocarcinoma related antigen, negative on mesotheliomas |
| MSH2 |
(Mismatch repair gene product) Subset of colorectal CA w/MSI |
| MSH6 |
(Mismatch repair gene product) Subset of colorectal CA w/MSI |
| MSI |
See MLH1, MSH2, MSH6, PMS2 |
| MTF |
(Microphthalmia transcription factor) Melanoma and melanocytic tumors |
| MUM1 |
Lymphoid/plasma cell specific marker |
| Muscle specific actins |
(HHF-35) Smooth, skeletal muscle differentiation: leiomyosarcoma, rhabdomyosarcoma, myofibroblasts, myoepithelium |
| Myeloperoxidase |
Granulocytes and histocytes, marker of leukemias |
| MyoD1 |
Rhabdomyosarcoma |
| Myogenin |
Rhabdomyosarcoma |
| Myoglobin |
Rhabdomyosarcoma |
| N |
|
| NB84 antigen |
Neuroblastoma and other small, blue round cell tumors |
| NCAM (CD56) |
Natural killer cells (NK/T cell lymphoma), neural tumors |
| NGFR |
Nerve growth factor receptor (p75-NTR); nerve sheath differentiation |
| Neurofilaments |
Neurons and neuronal tumors |
| O |
|
| Oct-2 |
B-cell transcription factor |
| Oct-3/4 |
Seminomatous/(dys)germinomatous tumors and embryonal carcinomas |
| P |
|
| p16 |
Evaluation of cervical intraepithelial lesions; surrogate marker of high-risk HPV |
| p21-WAF1 |
Tumor suppressor gene |
| p53 |
Tumor suppressor gene product overexpressed in subset of malignancies - marker of p53 mutation and poor prognosis |
| p57 |
Distinction between complete and partial hydatidiform moles |
| p63 |
Myoepithelial marker, in situ v. infiltrating breast carcinoma; squamous, transitional cell marker; lost in prostatic adenocarcinomas |
| p75-NTR |
Nerve growth factor receptor: nerve sheath differentiation |
| p80 (ALK protein) |
Anaplastic large cell lymphoma [subset with t(2;5)] |
| p504s (Human AMACR) |
Prostate carcinoma marker |
| Pancreatic polypeptide |
Subset of pancreatic islet cell tumors |
| Parathormone |
See PTH |
| Parvovirus |
Parvovirus identification |
| PAX-2 |
Renal cell carcinoma |
| PAX-5 |
B cell specific activator protein (BSAP) |
| PAX-8 |
Marker of GYN, renal and thyroid carcinomas |
| Pemphigoid (Bullous) |
Assessment of circulating antibodies using indirect immunofluorescence on monkey esophagus |
| Pemphigus (Vulgaris) |
Assessment of circulating antibodies using indirect immunofluorescence on monkey esophagus |
| Placental lactogen |
Intermediate trophoblasts |
| PLAP |
(Placental alkaline phosphatase) Seminoma |
| PMS2 |
DNA mismatch repair protein. This antibody will be of use in a panel of other antibodies to determine the presence of microsatellite instability. |
| Pneumocystis |
Pneumocystis identification |
| Podoplanin |
Lymphatic endothelium marker, distinguishes mesothelioma v. adenocarcinoma (D2-40) |
| Polyomavirus |
see SV40 |
| Prealbumin |
(Transthyretin) Choroid plexus tumors, some forms of amyloid |
| Progesterone receptor (PR) |
Breast (prognostic and predictive marker), meningiomas |
| Prolactin |
Subset of pituitary tumors |
| Prostate specific antigen |
(PSA) Prostate carcinoma |
| Prostatic acid phosphatase |
(PAP) Prostate carcinoma |
| PTH |
Parathyroid tissue and tumors |
| R |
|
| Renal cell carcinoma (gp200) |
Not currently available |
| Respiratory syncytial virus |
RSV identification |
| S |
|
| S-100 |
Melanoma, Schwann cells, neural support cells, Langerhans histiocytes |
| Serotonin |
Subset of carcinoid tumors |
| SMMHC |
(Smooth muscle myosin heavy chain) Myoepithelial marker; in situ vs. infiltrating breast carcinoma |
| Smoothelin |
Useful in the distinction of muscularis propria from muscularis mucosae of the urinary bladder: a potential ancillary tool in the pathologic staging of invasive urothelial carcinoma |
| Somatostatin |
Subset of pancreatic islet cell & other neuroendocrine tumors |
| Surfactant ApoA1 |
Lung non-small cell carcinoma marker |
| SV40 virus |
SV40 virus identification, PML; cross reacts with BK virus, JC virus, and polyomavirus |
| Synaptophysin |
Neuroendocrine differentiation (e.g., sm. cell CA), neuroblastoma |
| T |
|
| TCR-βF1 |
α-β T cells, and most neoplasms of these cells |
| TdT |
Lymphoblastic lymphoma |
| TFE3 |
Marker of alveolar soft part sarcoma and t(X;17) renal carcinomas |
| Thrombomodulin |
Mesothelioma |
| Thymidylate synthase |
Prognostic and predictive marker in GI and other carcinomas |
| Thyroglobulin |
Thyroid follicular tumors |
| Thyroid stimulating hormone |
Subset of pituitary tumors |
| TIA-1 |
(Cytotoxic granule protein) Anaplastic large cell lymphoma |
| TLE-1 |
Synovid sarcomas |
| Topoisomerase IIα |
Predictor of treatment response |
| Toxoplasma |
Positive identification of toxoplasma |
| TRAcP |
(Tartrate resistant acid phosphatase) Hairy cell leukemia |
| Transthyretin |
(Prealbumin) Choroid plexus tumors, some forms of amyloid |
| Tryptase |
Markers of mast cells and mast cell tumors |
| TTF-1 |
(Thyroid transcription factor-1) Lung and thyroid carcinomas |
| Type IV collagen |
Basement membrane protein, subset of mesenchymal tumors |
| Tyrosinase |
Melanoma |
| U |
|
| Uroplakin |
Urothelial carcinoma |
| V |
|
| Varicella-zoster |
Positive identification of varicella- zoster |
| VEGF |
Prognostic marker and target for anti-angiogenesis therapy |
| Villin |
Adenocarcinoma subset, especially gastrointestinal |
| Vimentin |
Sarcomas, lymphomas, coexpressed with cytokeratin in some carcinomas (e.g., renal cell and endometrial carcinomas) |
| VIP |
(Vasoactive intestinal polypeptide) Subset of neuroendocrine tumors |
| von Willebrand factor (vWF) |
(F. VIII related antigen) Endothelial cells, megakaryocytes |
| W |
|
| WT-1 |
(Wilms tumor gene product) desmoplastic small round cell tumor, mesothelioma, ovarian surface epithelial tumors |
| Z |
|
| ZAP-70 |
T cell marker, prognostic marker in CLL/SLL |
| Flow Cytometry "Tube" |
Antigens Evaluated |
| Mature B cell tube |
CD45, CD19, surface kappa & lambda, CD20, CD5, CD10, CD38, CD56 |
| B cell therapy add-on |
CD45, CD52, CD22, CD19, CD20, CD5, CD10, CD38 |
| CLL/SLL/Mantle cell lymphoma add-on |
CD45, CD19, CD5, FMC7, CD23, CD22, CD38, ZAP-70 |
| Hairy cell leukemia add-on |
CD45, CD19, CD103, CD25, CD11c, CD22, CD20 |
| Follicular lymphoma/Burkitt lymphoma add-on |
CD45, CD19, bcl-2, CD20, CD10, CD38, CD5 |
| Plasma cell neoplasm |
CD45, cytoplasmic kappa & lambda, CD19, CD38, CD138, CD56, CD20,
CD5 |
| Mature T cell tube |
CD45, CD3, CD2, CD4, CD5, CD7, CD8, CD34, CD56 |
| T cell therapy add-on |
CD45, CD3, CD52, CD30, CD25, CD4, CD8 |
| T cell receptor subtype add-on |
TCR-alpha/beta, TCR-gamma/delta, CD5, CD4, CD8, CD56 |
| T cell clonality |
24 TCR-beta isoforms, CD3, CD4,
CD8, other T cell antigens as needed |
| Precursor B lymphoblastic lymphoma/leukemia |
TdT, CD22, CD34, CD13, CD33,
HLA-DR, in addition to antigens in mature B cell tube above |
| Precursor T lymphoblastic lymphoma/leukemia |
TdT, CD1a, CD34, CD13, CD33,
HLA-DR, in addition to antigens in mature T cell tube above |
| Myeloid stem cell neoplasm (3 tubes) |
CD45, CD15, CD33, CD34, CD117, CD38, CD71, CD19, HLA-DR,
CD64, CD13, CD14, CD123, CD16, CD2, CD3, CD4, CD5, CD7, CD8, CD56 |
| Acute myeloid leukemia |
3 myeloid stem cell tubes plus additional blast antigens
(CD9, CD133, CD90); megakaryocytic antigens (CD41, CD61) evaluated as needed |
| Cytoplasmic lineage add-on (if
blast lineage is uncertain) |
CD45, CD34, cytoplasmic myeloperoxidase, CD3, CD79a |
| Paroxysmal nocturnal hemoglobinuria (PNH) |
CD59 (erythrocytes), FLAER, CD14 (monocytes), CD66b (neutrophils), CD24 (neutrophils), plus gating antibodies |
| Small blue round cell tumors (favor non-hematopoietic) |
CD45, EpCAM (epithelial cell
adhesion marker), CD99, CD90, CD56, CD10, CD38 |
| Test Menu
Name |
Test # |
Useful Application/Cells/Tumors Identified |
CPT code(s) |
Specimen source |
| FFPE Material * |
Fresh Material ** |
| Solid Tumors |
1p36/19q13 – Oligodendroglioma panel
|
FISH0013 |
Oligodendrogliomas, mixed oligoastrocytomas
Includes:
- 1p36/1q25 (1p36 deletion)
- 19q13/19p13 (19q13 deletion)
|
88368 (4) |
X |
|
| EGFR/CEP7 |
FISH0016 |
Colorectal, breast and non-small cell lung carcinomas, and glioblastoma multiforme. EGFR gene amplification by FISH may identify tumors predicting responsiveness to EGFR-targeted therapies |
88367 (2) |
X |
|
| EWSR1 (22q12) translocations (Breakapart) |
FISH0004 |
Clear cell sarcoma, Extraskeletal myxoid chondrosarcoma, PNET/Ewing sarcoma, Desmoplastic small round cell tumor |
88367 (2) |
X |
|
| HER2/CEP17 (PathVysion™) |
FISH0001 |
Identifies the subset of breast carcinoma patients eligible for Herceptin™ (trastuzumab) therapy. |
88367 (2) |
X |
|
| TP53/CEP17 |
FISH0024 |
Provides information on the chromosome 17 copy number. May provide additional information re: HER2 amplification status when the CEP17 signal number is increased or decreased. This may aid clinicians in choosing appropriate therapy. |
88367 |
X |
|
| SMS/RARA |
FISH0022 |
Provides information on the chromosome 17 copy number. May provide additional information re HER2 amplification status when the CEP17 signal number is increased or decreased. This may aid clinicians in choosing appropriate therapy. |
88367 (2) |
X |
|
| MDM-2/SE12 |
FISH0023 |
Well-differentiated liposarcoma, dedifferentiated liposarcoma, atypical lipomatous tumor, and pleomorphic lipoma |
88367 (2) |
X |
|
| SS18 (SYT) translocations (Breakapart) |
FISH0006 |
Synovial Sarcoma |
88367 (2) |
X |
|
| TOP2A / CEP17 |
FISH0017 |
A predictive biomarker in a subset of breast carcinomas. TOP2A gene amplification may predict response to anthracycline-containing breast chemotherapy. |
88367 (2) |
X |
|
| Lymphomas |
| B cell, non-Hodgkin lymphoma (NHL) |
N/A |
PhenoPath pathologists will select an appropriate panel based on clinical history. Panel may include some or all of the following:
Other tests may be added as medically necessary |
|
|
|
| BCL6 (3q27) translocations (Breakapart) |
FISH0018 |
Subset of follicular lymphoma and DLBCL. Identifies t(3;14) and other translocations involving the BCL6 gene. |
88367 (2) |
X |
|
| IGH (14q32) translocations (Breakapart) |
FISH0015 |
Lymphomas with IGH translocations involving the IGH gene on 14q32 |
88367 (2) |
X |
X |
| MALT1 (18q21) translocations (Breakapart) |
FISH0007 |
Translocations involving the MALT1 gene have been detected in approximately 20-30% of patients with extranodal low grade marginal zone B-cell lymphomas of MALT type (i.e., MALT lymphomas). Patients with t(11;18)(q21;q21)-positive gastric MALT lymphomas do not respond to Helicobacter pylori eradication therapy, are associated with more advance stage disease, and usually do not show transformation to large cell lymphoma. |
88367 (2) |
X |
|
| t(14;18) IGH/MALT1 |
FISH0008 |
Subset of MALT lymphomas (Marginal zone B cell lymphoma) |
88367 (2) |
X |
|
| t(11;18), MALT1/API2 |
FISH0003 |
Subset of MALT lymphomas (Marginal zone B cell lymphoma) |
88367 (2) |
X |
|
| MYC Panel |
PANL9101 |
Useful in Burkitt lymphoma and other aggressive B-cell lymphomas
|
88367(4) |
X |
X |
| t(4;14) FGFR3/IGH |
FISH0020 |
Identifies a subset of plasma cell neoplasms. The presence of t(4:14)(p16;q32) involving IgH/FGFR has been associated with a poor prognosis with shorter overall survival. |
88367 (2) |
X |
|
| t(14;16) IGH/MAF |
FISH0027 |
Identifies a subset of plasma cell neoplasms. The presence of t(14;16)(q32;q23) involving IgH/MAF has been associated with a poor prognosis with shorter overall survival. |
88367 (2) |
X |
|
| t(11;14) CCND1/IGH |
FISH0002 |
Identifies mantle cell lymphoma and subset of plasma cell neoplasms. Patients with multiple myeloma that have a t(11;14)(q13;q32) have been reported to have a neutral to slightly improved clinical course. FISH-based assays provide the most sensitive and specific methodology for detecting the t(11;14)(q13;q32). |
88367 (2) |
X |
X |
| t(14;18) IGH/BCL2 |
FISH0005 |
Identifies follicular lymphoma and subset of DLBCL with the t(14;18)(q32;q21), which results in constitutive overexpression of the BCL-2 protein leading to alterations in programmed cell death (i.e., apoptosis) and tumor cell proliferation. FISH-based assays provide the most sensitive and specific methodology for detecting the t(14;18)(q32;q21). |
88367 (2) |
X |
X |
| Leukemias |
APL Panel (Acute Promyelocytic Leukemia)
|
PANL9103 |
Useful in diagnosing promyelocytic (AML-M3) leukemia and identifying the common t(15;17) and variants.
|
|
|
|
| t(9;22) BCR/ABL |
FISH0010 |
CML and subset of ALL. CML has been traditionally diagnosed by detection of a Philadelphia chromosome (Ph) which has become the hallmark of this disease and is the result of a reciprocal translocation between the BCR gene on chromosome 22 and the ABL gene on chromosome 9. Detection of the Philadelphia chromosome by FISH (or other techniques) helps to confirm and/or monitor patients with CML or other myeloproliferative disorder. An alternate translocation involving BCR and ABL, which is also detected by this assay, can be seen in acute lymphoblastic leukemia (ALL). |
88368 (2) |
X |
X |
| MLL (11q23) translocations (Breakapart) |
FISH0014 |
AML, ALL, and mixed lineage acute leukemias. Translocations involving the MLL gene on chromosome 11q23 are noted in a subset of acute myeloid leukemias (AML) and acute lymphoblastic leukemias/lymphomas (ALL).1Moreover, treatment-related leukemias, 5-10%, particularly those following anti-topoisomerase II or intercolating topoisomerase II inhibitors, but also alkylating therapy or radiotherapy, often have translocations involving 11q23. The detection of translocations involving MLL is important in the diagnosis of patients with AML and ALL as they predict a poor overall prognosis. |
88368 (2) |
|
X |
| t(15;17) PML/RARA |
FISH0011 |
AML-M3 Proper subclassification of this leukemia is critical for optimal patient management (i.e., to alert the treating oncologist that there is a significant risk of DIC). In fact, the presence of a PML/RARA gene rearrangement is directly related to patients with AML-M3 who respond to ATRA therapy. FISH tests can be used to establish a definitive diagnosis of APL. This test is not intended to detect minimal residual disease. |
88368 (2) |
|
X |
| RARA (17q21) translocations (Breakapart) |
FISH0019 |
AML-M3, t(17;V). Typically used in conjunction with the t(15;17) PML/RARA away (# FISH0011) in the diagnosis of AML-M3. Specifically detects variant PRARA translocations. The three variant translocations involving the RARA gene include:
- t(11;17)(q23;q21) involving the promyelocytic leukemia zinc finger gene (PLZF) on 11q23,
- t(5;17)(q23;q21) involving the nucleophosmin (NPM) on 5q23, and
- t(11;17)(q23;q21) involving the nuclear matrix associated gene (NUMA) on 11q13.
Acute promyelocytic leukemias involving the variant t(11;17)(q23;q21) have been reported to be resistant to ATRA whereas those with variant t(5;17)(q23;q21) appear to respond to ATRA.6 Results of this test must always be interpreted in the context of morphologic and other relevant data, and should not be used alone for the diagnosis of malignancy. This test is not intended to detect minimal residual disease. |
88367 (2) |
X |
|
| Plasma Cell Neoplasms |
| Plasma Cell / Myeloma FISH panel |
|
Panel of tests for identification of plasma cell neoplasms. See details below.
- IGH (14q32) BAP (FISH 0015)
- t(11;14) CCND1/IGH (FISH 0002)
If IGH is positive and CCND1 is negative, we will run…
- t(4;14) FGFR3/IGH (FISH0020)
- t(14;16) IGH/MAF (FISH0027)
|
|
X |
X |
| IGH (14q32) translocations (Breakapart) |
FISH0015 |
Lymphomas with IGH translocations involving the IGH gene on 14q32 |
88367 (2) |
X |
X |
| t(11;14) CCND1/IGH |
FISH0002 |
Identifies mantle cell lymphoma and subset of plasma cell neoplasms. Patients with multiple myeloma that have a t(11;14)(q13;q32) have been reported to have a neutral to slightly improved clinical course. FISH-based assays provide the most sensitive and specific methodology for detecting the t(11;14)(q13;q32). |
88367 (2) |
X |
X |
| t(4;14) FGFR3/IGH |
FISH0020 |
Identifies a subset of plasma cell neoplasms. The presence of t(4:14)(p16;q32) involving IgH/FGFR has been associated with a poor prognosis with shorter overall survival. |
88367 (2) |
X |
|
| t(14;16) IGH/MAF |
FISH0027 |
Identifies a subset of plasma cell neoplasms. The presence of t(14;16)(q32;q23) involving IgH/MAF has been associated with a poor prognosis with shorter overall survival. |
88367 (2) |
X |
|
| Other |
| Hydatidiform Mole panel |
PANL9103 |
Useful in distinguishing partial hydatidiform mole (PHM) vs. complete hydatidiform mole (CHM) vs. hydropic villi in products of conception (POC).
|
88367
88342
88360
|
X
X
X
|
|
| CEP-X/CEP-Y |
FISH0012 |
Useful in detection of tissue contaminants/floaters by identification of chromosome X or Y; also in assessment of sex-mismatched BMT |
88365 (2) |
X |
|
| EBV (EBER1 mRNA by ISH) |
CISH0001 |
Post transplantation lymphoproliferative disorder, Hodgkin lymphoma, EBV identification |
88365 |
X |
|
